EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 797 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR New plan unveiled to tackle Scotland’s cancer crisis June 16, 2023 European Lung Cancer Congress 2025, Paris, France, 26-29 March 2025 March 20, 2025 Taking Control – Risks vs. Benefits July 14, 2020 The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable... July 1, 2021 Load more HOT NEWS Doctor Wipes Away The Debt Of 200 Cancer Patients Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small... Understanding Genomic Correlates of Response and Acquired Resistance to FGFR Inhibitors How to Be Brave When Your Parent Has Cancer: A Kid’s...
